UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
January 24, 2005
(Date of earliest event reported)
LABORATORY CORPORATION
OF
AMERICA HOLDINGS
| DELAWARE | 1-11353 | 13-3757370 | ||
| (State or other jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA |
27215 | 336-229-1127 | ||
| (Address of principal executive offices) | (Zip Code) |
(Registrant's telephone number including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
On January 24, 2005 — Laboratory Corporation of America® Holdings (LabCorp®) announced that Executive Vice President for Corporate Affairs, Bradford T. Smith, is scheduled to speak at the Piper Jaffray Health Care Conference in New York, NY on January 25, 2005 at 9:30 a.m. Eastern Time. A live audio webcast of the presentation will be available via the Company web site at www.labcorp.com. An archived replay of the audio webcast will be available for 30 days following the conference.
Exhibits
99.1 Press Release dated January 24, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Laboratory Corporation of America Holdings (Registrant) |
||||
| Date: January 24, 2005 | By: | /s/Bradford T. Smith | ||
| Bradford T. Smith, Executive Vice President and Secretary |
||||
Exhibit 99.1
Laboratory Corporation of
America® Holdings
358 South Main Street
Burlington, NC 27215
Telephone:(336) 584-5171
FOR IMMEDIATE RELEASE
Contact: Brad Hayes
Shareholder Direct: (800)LAB-0401
Company Information: www.LabCorp.com
LABCORP®
SCHEDULED TO PRESENT AT THE
PIPER JAFFRAY HEALTH
CARE CONFERENCE
Burlington, NC, January 24, 2005 — Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that Executive Vice President for Corporate Affairs, Bradford T. Smith, is scheduled to speak at the Piper Jaffray Health Care Conference in New York, NY on January 25, 2005 at 9:30 a.m. Eastern Time.
A live audio webcast of the presentation will be available via the Company web site at www.labcorp.com. An archived replay of the audio webcast will be available for 30 days following the conference.
About LabCorp
Laboratory Corporation of
America® Holdings is a pioneer in commercializing new diagnostic technologies and the
first in its industry to embrace genomic testing. With annual revenues of $2.9 billion in
2003, approximately 23,000 employees nationwide, and more than 220,000 clients, LabCorp
offers over 4,400 clinical assays ranging from blood analyses to HIV and genomic testing.
LabCorp combines its expertise in innovative clinical testing technology with its Centers
of Excellence: The Center for Molecular Biology and Pathology, in Research Triangle Park,
NC; National Genetics Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based
in Minneapolis, MN; The Center for Esoteric Testing in Burlington, NC; and DIANON
Systems, Inc. based in Stratford, CT. LabCorp clients include physicians,
government agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our growing organization, visit our web site
at: www.LabCorp.com.
Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp’s financial results is included in the Company’s Form 10-K for the year ended December 31, 2003, and subsequent SEC filings.